We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Model Outperforms Clinicians in Rare Disease Detection

By LabMedica International staff writers
Posted on 04 Mar 2026

Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. More...

Many conditions present with heterogeneous signs that overlap with common disorders, leading to repeated referrals, misdiagnosis, and unnecessary procedures. For many patients, time to a confirmed diagnosis can exceed five years. A new study now shows that an artificial intelligence (AI) system can outperform experienced clinicians in identifying rare diseases earlier and more accurately.

A team led by researchers at Shanghai Jiao Tong University and affiliated institutions has developed DeepRare, an agentic framework for rare-disease prioritization and diagnosis. Rather than relying on a single model, the system coordinates 40 specialized digital tools to analyze diverse inputs, including a patient’s DNA, official medical databases, and handwritten clinical notes. A central AI host orchestrates these components to synthesize evidence and converge on a diagnosis with traceable reasoning.

DeepRare was first evaluated on 6,401 clinical cases with known outcomes. Using the same symptom and DNA information available to the original clinicians years earlier, the system could have identified the correct condition earlier in the diagnostic process. In this retrospective benchmark, it also outperformed 15 existing diagnostic systems.

A subsequent head-to-head assessment tested DeepRare against physicians on 163 difficult cases. Five experienced doctors, each with more than a decade of practice, received the same data as the system. DeepRare achieved a 64.4% top-1 diagnostic accuracy on the first attempt, compared with 54.6% for the physicians.

Even when not exactly correct on the first try, the model’s Recall@3 indicated that the right diagnosis was usually among its top three suggestions. Ten rare-disease specialists reviewed the system’s step-by-step reasoning and agreed with its logic 95.4% of the time. The findings were detailed in a study published in Nature on February 18, 2026.

"DeepRare is one of the first computational models to surpass the diagnostic performance of expert physicians in the complex task of rare-disease phenotyping and diagnosis," stated the study's authors. "Our work not only advances rare disease diagnosis but also demonstrates how the latest powerful large-language-model-driven agentic systems can reshape current clinical workflows."

Related Links:
Shanghai Jiao Tong University


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.